Brief: AcelRx Pharmaceuticals Announces Publication Of Results From A Clinical Study Assessing Use Of Sufentanil Sublingual Tablet For Painful Radiofrequency Microneedling Procedures
31/03/2022 22:12
March 31 (Reuters) - AcelRx Pharmaceuticals Inc ACRX.O :
* ACELRX PHARMACEUTICALS ANNOUNCES PUBLICATION OF RESULTS
FROM A
CLINICAL STUDY ASSESSING USE OF SUFENTANIL SUBLINGUAL TABLET FOR
PAINFUL RADIOFREQUENCY MICRONEEDLING PROCEDURES
Source text for Eikon: ID:nPn6fpGKza
Further company coverage: ACRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial